Biotech Values

[oc631]

Please clarify.

Considering the resistance profile of the nucleotide class it will be years before viral mutation requires an additional drug like DEB-025 in the first line setting. By that time the majority of patients in the developed world will have been treated and hopefully will have achieved a SVR. Misuse of the drug in the undeveloped world will lead to increased chances of viral mutation.